期刊文献+

冻干重组人三突变型低氧诱导因子-1α腺病毒的制备

Preparation of freeze-dried recombinant adenovirus expressing hypoxia inducible factor-1 alpha of triple mutant
下载PDF
导出
摘要 目的:研制冻干重组人三突变型低氧诱导因子-1α(HIF-1α)腺病毒。方法:将重组人三突变型HIF-1α腺病毒与不同配比的保护剂按适当比例混合,进行冻干,根据冻干后外观、病毒滴度测定、热稳定性试验、PCR、基因测序等结果,筛选冻干保护剂并评价冻干品质量。结果:冻干腺病毒所携带的目的基因信息无丢失或变异;以10%海藻糖、0.5%明胶、3%山梨醇等成分配制的保护剂作用较好,冻干后腺病毒感染性滴度下降0.33LgPFU/mL;37℃放置3周,滴度下降0.8LgPFU/mL。结论:以合适的保护剂制备冻干重组人三突变型HIF-1α腺病毒能达到较满意的效果。 Objective To prepare freeze-dried recombinant adenovirus expressing hypoxia inducible factor-I alpha (HIF-1α) of triple mutant (Ad-H1F-1α-564/402/803). Methods Ad-HIF-1α-564/402/803 were mixed with different stabilizers in an appropi:iate propollion and then lyophilized. The optimum stabilizer was selected and the product quality was evaluated according to appearance, virus titer, thermostability, PCR and DNA sequence analysis. Results PCR and gene sequence suggested the correct construction of freeze-dried recombinant adenovirus. The protective agent containing 10% trehalose, 0.5% gelatin, 3% sorbitol had better protecting effects, After lyophilization, the infectious titer of adenovlrus was decreased by 0.33 LgPFU/mL, the titer of lyophilized adenovirus was decreased by 0.8 LgPFU/mL for 3 weeks at 37℃. Conclusions When prepared with proper stabilizer, the freeze-dried recombinant adenovirus expressing HIF-1α of triple mutant can have a good performance.
出处 《实用医学杂志》 CAS 北大核心 2011年第3期369-371,共3页 The Journal of Practical Medicine
基金 国家自然科学基金资助项目(编号:30370587)
关键词 缺氧诱导因子1 重组腺病毒 冷冻干燥 保护剂 制备 Hypoxia-indueible factor 1 Recombinant adenovirus Lyophilization Stabilizer Preparation
  • 相关文献

参考文献10

二级参考文献41

  • 1王弘,郑文岭.基因治疗发展研究现状[J].实用医学杂志,2004,20(10):1199-1200. 被引量:1
  • 2李建勇,王彬尧,王长谦,厉锦华,李慧丽,胡大一.HIF-1基因治疗促进缺血心肌血管新生的实验研究[J].中国心血管病研究,2005,3(9):709-711. 被引量:11
  • 3王韵,曹旭,高山红,李雪芹,张晶,王淑真,周玲,张福利,章新华,洪洋,王怀良.腺苷对家兔心肌缺血再灌注损伤的保护作用[J].中国医科大学学报,2006,35(6):568-570. 被引量:4
  • 4Shyu K G,Wang M T,Wang B W,et al.Intramyocardial injection of naked DNA encoding HIF-1alpha/VPI6 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat[J].Cardiovasc Res,2002,54(3):576-583.
  • 5Rajagopalan S,Olin J,Deitcher S.et al.Use of a constitutively active hypoxia-indueible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients:phase Ⅰ doseescalation experience[J].Circulation,2007,115 (10):1234-1243.
  • 6Tongers J,Roncalli J G,Losordo D W.Therapeutic angiogenesis for critical limb ischemia:microvascular therapies coming of age[J].Circulation,2008,118 (1):9-16.
  • 7Vincent K A,Shyu K G,Luo Y,et al.Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor[J].Circulation,2000,102 (18):2255-2261.
  • 8Fam NP, Verma S, Kutryk M, et al. Clinician guide to angiogenesis [J]. Circulation, 2003, 108(21): 2613-8.
  • 9Lee JW, Bae SH, Jeong JW, et al. Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions [J]. Exp Mol Med, 2004, 36(1): 1-12.
  • 10Pereira T, Zheng X, Poellinger L. Degradation of the hypoxia- inducible factor 1 alpha: where does it happen [J]? Cell Cycle, 2006, 5(23): 2720-2.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部